All In Biotech

Drug Trial Radar · NCT07899346

Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome (FLINTLOCK)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Invivyd, Inc.Industry
Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept study is being conducted to investigate the safety (whether there are any side effects), tolerability (if it does cause side effects, how well your body handles them), pharmacokinetics (PK) (how a drug is taken into your body, spread throughout, broken down, and eliminated), clinical activity (does the drug make patients feel better), immunogenicity (how the immune system responds to the drug), and serum virus neutralizing antibody response (antibodies that block a virus from infecting cells) of VYD2311, the investigational monoclonal antibody being studied, in adults with Long-COVID or Post-Vaccination Syndrome. Participants will receive an intravenous (IV) infusion on Day 1 of either the investigational drug or placebo followed by two intramuscular (IM) injections (a shot in the upper arm), one on day 30 and the other on Day 60. The IM injections will also either be investigational drug or placebo. The participants will be then asked to complete a 30-day follow up period and end the study on day 90.

Conditions

  • Long COVID
  • COVID-19 (SARS-CoV-2 Infection)
  • COVID 19 Vaccine
  • COVID Long

Interventions

  • VYD2311Drug

    Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with VYD2311

  • PlaceboDrug

    Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with placebo (normal saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90Time frame: 90 days
  2. Serum concentrations of VYD2311 through Day 90Time frame: 90 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.